Skip to main content

Featured

Canadian Money Brief: 5 Things to Know Today — May 27, 2026

  From a blockbuster bank earnings day to a historic energy deal with Europe, here are the five stories driving Canadian markets and your money this Wednesday morning. 1. Big Bank Earnings Are In — All Eyes on RBC, BMO & Scotiabank It's the biggest day on the Canadian earnings calendar this week. Royal Bank of Canada , Bank of Montreal , Scotiabank , and National Bank of Canada are all reporting their Q2 fiscal 2026 results today. TD Bank follows tomorrow. Heading into the reports, markets have been cautious — the TSX's banking sector was largely flat on Tuesday as investors held off placing big bets ahead of the numbers. All six major banks beat analyst expectations in Q1, so the bar is set high. Watch for any commentary on loan loss provisions and whether executives flag concern about the economic impact of ongoing U.S. tariffs. These results will set the tone for the TSX's largest sector for weeks to come. 2. Canada Signs Historic LNG Deal With Germany In a landmark...
Post a Comment
Read more

article

Labels

Revolutionary Gene Therapy Restores Hearing in Deaf Toddler

 

In a remarkable medical breakthrough, an 18-month-old toddler named Opal Sandy has regained her hearing thanks to a pioneering gene therapy trial. Born deaf due to a rare genetic condition affecting the OTOF gene, which is responsible for producing a protein essential for hearing, Opal’s prospects for natural hearing were bleak. However, the innovative treatment at Cambridge University Hospitals in England has opened up a world of sound for her.

The procedure involved the infusion of a working copy of the OTOF gene into Opal’s right ear, a process that took a mere 16 minutes. Remarkably, within weeks, Opal began responding to loud noises, and after 24 weeks, she could hear whispers, indicating a near-normal level of hearing restoration.

Opal’s case is part of the Chord trial, which is recruiting more children from the UK, Spain, and the US to undergo similar treatment. The trial is being closely monitored, with participants followed up for five years to assess the long-term efficacy and safety of the therapy.

The success of this gene therapy is a beacon of hope for many suffering from genetic deafness, signaling the dawn of a new era in medical science where conditions once thought incurable are now within the realm of treatment. Opal’s story is not just a personal victory; it’s a milestone in genetic medicine, showcasing the incredible potential of gene therapy to change lives.

Labels:

Comments

Post a Comment